COMPASS Pathways plc CMPS
As ofNov 20, 2026, 11:49 AM EST
- YTD
- +17.46%
- 1 year
- +55.87%
5D -0.81 (-9.08%)
- Market cap
- 1.15B
- EPS (ttm)
- -2.34
- Shares out
- 141.71M
- Forward P/E
- -5.47
- YTD return
- +17.46%
- 1-year return
- +55.87%
- 50-day average
- 11.53
- 200-day average
- 10.51
- Enterprise value
- 761.10M
- Price / book
- 8.62
- Volume
- 2.34M
- Avg volume
- 3.03M
- Open
- 8.32
- Previous close
- 8.65
- Day's range
- 7.82 – 8.43
- 52-week range
- 4.88 – 15.87
- Beta
- 2.41
- Analysts
- Strong Buy
- Price target
- 23.31 (+187.6%)
- Earnings date
- Mar 23, 2027
Key statistics
- Free cash flow
- 36.26M
- Total cash
- 443.98M
- Total debt
- 54.39M
- Return on equity
- -296.45%
- Short % of float
- 12.29%
Fundamental scorecard
3 of 25 checks passed on CMPS’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 10.00
- Target (mean)
- 23.31
- Target (high)
- 65.00
- Strong buy3
- Buy12
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 23, 2027
Expected Mar 23, 2027. Consensus EPS estimate -0.465.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 23, 2027 | Dec 30, 2026 | -0.40 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -0.39 | -0.31 | +0.08 | +20.51% |
| Aug 5, 2026 | Jun 30, 2026 | -0.46 | -0.36 | +0.10 | +21.74% |
| May 13, 2026 | Mar 31, 2026 | -0.45 | -0.30 | +0.15 | +33.33% |
| Mar 24, 2026 | Dec 31, 2025 | -0.41 | -1.00 | -0.59 | -143.90% |
| Nov 4, 2025 | Sep 30, 2025 | -0.40 | -1.44 | -1.04 | -260.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 4, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Nov 3, 2026 | BTIG | reit | Buy | Buy |
| Aug 7, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 6, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Aug 6, 2026 | RBC Capital | main | Outperform | Outperform |
About COMPASS Pathways plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Country
- United Kingdom
- Website
- compasspathways.com
News
Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 1 Compass Pathways Submits FDA New Drug Application For Comp360 Psilocybin For Treatment-Resistant Depression
HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $65 Price Target
Wells Fargo Maintains Equal-Weight on Compass Pathways, Lowers Price Target to $10
12 Health Care Stocks Moving In Tuesday's Pre-Market Session Compass Pathways Q3 EPS $(0.31) Beats $(0.43) Estimate
Compass Pathways Issues New Report Summarizing Findings From National Survey Of People Living With TRD And Caregivers On The Burden Of Prolonged Depressive Episodes Without Meaningful Relief
Your note
Sign in to keep a note on CMPS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LOXAM TERI | Chief Financial Officer | Stock Award(Grant) | Mar 25, 2026 | 152,002 |
| NATH KABIR | Chief Executive Officer | Stock Award(Grant) | Mar 25, 2026 | 366,990 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deep Track Capital, Lp | 8.58% | 12,161,496 | 105.20M | Sep 29, 2026 |
| RTW Investments LP | 7.73% | 10,948,591 | 94.71M | Sep 29, 2026 |
| BIT Capital GmbH | 6.33% | 8,968,094 | 77.57M | Sep 29, 2026 |
| Tang Capital Management, LLC | 3.67% | 5,200,000 | 44.98M | Sep 29, 2026 |
| ARK Investment Management, LLC | 3.46% | 4,905,613 | 42.43M | Sep 29, 2026 |
| Point72 Asset Management, L.P. | 3.34% | 4,737,706 | 40.98M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Genomic Revolution ETF | 3.57% | 5,058,583 | 43.76M | Oct 30, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.63% | 886,679 | 7.67M | Sep 29, 2026 |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.32% | 458,395 | 3.97M | Oct 30, 2026 |
| ROYCE FUND-Royce Smaller-Companies Growth Fund | 0.13% | 178,000 | 1.54M | Jun 29, 2026 |
| ALPS ETF TRUST-ALPS Medical Breakthroughs ETF | 0.12% | 166,501 | 1.44M | Aug 30, 2026 |
| Goldman Sachs Trust-Goldman Sachs Small Cap Growth Fund | 0.11% | 152,301 | 1.32M | Aug 30, 2026 |
